This technology identifies urine biomarkers that distinguish between two types of acute kidney injury (AKI) and recommends treatments based on the identified subtype.
Acute Kidney Injury (AKI) is common among hospitalized patients, increasing the risk of developing further conditions such as kidney disease, stroke, or heart disease. AKI presents in various forms, notably volume-dependent (vAKI) and ischemic (iAKI); however, the biological distinction between these two forms of AKI is not well understood and their appropriate treatments are not optimized. Identifying key biomarkers distinguishing the forms of AKI will improve diagnosing the condition, and guide the appropriate therapeutic interventions.
This technology describes a method of using protein biomarkers present in the urine to rapidly diagnose, differentiate between, and treat vAKI and iAKI. In particular, four key protein biomarkers are identified that not only indicate AKI but also distinguish between vAKI and iAKI based on characteristic expression patterns. By rapidly identifying AKI and distinguishing between subtypes, this technology provides a clinical tool for improved diagnosis and management of kidney injury. This technology also provides specific treatment regimens based on AKI subtype.
This technology has been validated in a mouse model and human patient samples.
IR CU15143, CU14107, and CU16270
Licensing Contact: Kristin Neuman